GBM tissues; noncancerous tissues; glioma tissues; normal brain tissues
U87-MG; U251-MG; A172; T98G; HEBs; HEK293T
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); ceRNA regulation (promotes); other pathway/process (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis
High circFOXO3 expression was significantly associated with tumor size, histologic grade, wild-type IDH expression, and MGMT methylation status; circFOXO3 was proposed as a potential therapeutic target in GBM.
circFOXO3 (hsa_circ_0006404) is up-regulated in GBM tissues and GBM cell lines. It promotes GBM proliferation, invasion, migration, and xenograft tumor growth by acting as a cytoplasmic ceRNA that sponges miR-138-5p and miR-432-5p to increase NFAT5 expression. High circFOXO3 expression is associated with tumor size, histologic grade, IDH status, and MGMT methylation status, supporting its potential as a therapeutic target.
0.8689
CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5.
combined biological and clinical study